Quality of life in perimenopausal women with climacteric syndrome treated with the pineal hormone melatonin
Objective. To assess the quality of life in perimenopausal women with climacteric syndrome treated with melatonin.Usoltseva E.N.
Subjects and methods. Seventy women aged 53.6±5.5 years, who had taken melatonin 3 mg before bedtime for three months, were examined. The investigators evaluated the efficiency of the treatment, by using the Kupperman index, and assessed the quality of life by the SF-36 and WHQ questionnaires before treatment and 1 and 3 months after follow-up.
Results. Neuroautonomic, metabolic, endocrine, and psychoemotional symptoms were relieved three months after treatment. The SF-36 data showed that physical functional and role physical functioning were statistically significantly increased, and WHQ indicated a reduction in somatic symptoms, sleep problems, depression, and anxieties/fears.
Conclusion. The pineal hormone melatonin is effective in the treatment of mild climacteric syndrome and improves some quality-of-life indices in female women.
Keywords
climacteric syndrome
quality of life
melatonin
melaritm
Supplementary Materials
- Figure 1. Dynamics of climacteric symptoms on the background of treatment by melatonin as per MMI data
- Figure 2. Dynamics of patients quality of life according to the SF-36 general questionnaire while treatment by melatonin
- Figure 3. Dynamics of women's quality of life according to a WHQ special questionnaire while treatment by melatonin
References
1. Yureneva S.V., Ilyina L.M., Yakushevskaya O.V. Menopausal hormonal therapy in a postmenopause: quality of life today and in the long term. Ginekologiya/Gynecology. 2016; 18(1): 24-29. (in Russian)
2. Karasek M. Does melatonin play a role in aging processes? J. Physiol. Pharmacol. 2007; 58(Suppl. 6): 105-13.
3. Prilepskaya V.N., Bogatova I.K., Radzinskiy V.E. New in prophylaxis and therapy of a menopausal syndrome. Ginekologiya/Gynecology. 2016; 18(1): 7-12. (in Russian)
4. Ivanova O.V., Usoltseva E.N., Bryuhina E.V. Validation of the Russian-language version of a questionnaire of WOMEN’S HEALTH QUESTIONNAIRE (WHQ). Vestnik mezhnacional’nogo issledovanija kachestva zhizni/Bulletin of the Multinational Center of Quality of Life Research. 2011; 17-18: 58-68. (in Russian)
5. The instruction for data processing, received by means of the SF-36 questionnaire. http://www.cpr.spb.ru/question/sf-36_guidelines.rtf (in Russian)
6. Kolesnikova L.I., Madaeva I.M., Semenova N.V., Solodova E.I., Darenskaya M.A. The antioxidant system and the processes of lipid peroxidation in women with postmenopause sleep disorders. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2015; (6): 98-103. (in Russian)
7. Anisimov V.N., Vinogradova I.A. Aging of female reproductive system and melatonin. St. Petersburg: Publishing house «Sistema»; 2008: 44p. (in Russian)
8. Gafarova E.A., Maltseva L.I. The use of melatonin in obstetric practice. Ginekologiya/Gynecology. 2014; 6: 25-28. (in Russian)
9. Kuznetsova I.V., Burchakov D.I. Melatonin in treatment of climacteric symptoms. Ginekologiya/Gynecology. 2015; 17(5): 44-8. (in Russian)
10. Amstrup A.K., Sikjaer T., Mosekilde L., Rejnmark L. The effect of melatonin treatment on postural stability, muscle strength, and quality of life and sleep in postmenopausal women: a randomized controlled trial. Nutr. J. 2015; 14: 102. doi: 10.1186/s12937-015-0093-1.
11. Kotlarczyk M.P., Lassila H.C., O’Neil C.K., D’Amico F., Enderby L.T., Witt-Enderby P.A. et al. Melatonin osteoporosis prevention study (MOPS): a randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women. J. Pineal Res. 2012; 52(4): 414-26. doi: 10.1111/j.1600-079X.2011.00956.x.
12. Wade A.G., Ford I., Crawford G., McMahon A.D., Nir T., Laudon M. et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr. Med. Res. Opin. 2007; 23(10): 2597-605. doi: 10.1185/030079907X233098.
13. Wade A.G., Ford I., Crawford G., McConnachie A., Nir T., Laudon M. et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010; 8: 51. doi: 10.1186/1741-7015-8-51.
14. Levakov S.A., Borovkova E.I. Possibilities of use a melatonin for improvement of patient’s quality of life with a premenstrual and climacteric syndrome. Consilium Medicum. 2015; 6: 11-5. (in Russian)
15. Glazunova A.V., Yureneva S.V., Ezhova L.S. Vulvovaginal atrophy: Symptoms, impact on emotional well-being, quality, and sexual function. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2015; (12): 97-102. (in Russian)
Received 28.10.2016
Accepted 11.11.2016
About the Authors
Usoltseva Elena Nikolaevna, PhD, assistant of Obstetrics and gynecology department of the Additional Professional Education Institute of South-Ural Medical University, Ministry of Health of Russia. 454092, Russia, Chelyabinsk, Vorovsky str. 64. Tel.: +79124700092. E-mail: elena-usoltseva@yandex.ru. ORCID ID 0000-0002-9644-0216For citations: Usoltseva E.N. Quality of life in perimenopausal women
with climacteric syndrome treated with the pineal hormone melatonin.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (6): 104-10. (in Russian)
http://dx.doi.org/10.18565/aig.2017.6.104-10
Similar Articles
